Grifols is a leader in plasma collection with a network of more than 170 plasma donation centers in the U.S., and is a leading producer of plasma-derived medicines.
The company is present in more than 100 countries worldwide, with headquarters located in Barcelona, Spain. Grifols is a global healthcare company with more than a 75-year legacy of improving people's health and well-being through the development of protein therapies, hospital pharmacy products and diagnostic technology for clinical use. The agreement leverages Grifols' strength in manufacturing reliable instruments and reagents with that of Beckman Coulter's commercial strength," added Oriol Duñach, Grifols President of Diagnostic Industrial Division.īeckman Coulter and Grifols anticipate first commercializing systems under this distribution agreement in Europe in early 2018. "We are extremely excited about the collaboration with Beckman Coulter. "Grifols' hemostasis product line, focused on reliability and efficiency, combined with our global distribution network, automation leadership and clinical informatics solutions for the core laboratory, provide our customers with even more solutions to deliver better patient care," added Kevin Chance, President of Products and Services for Beckman Coulter Diagnostics. " Beckman Coulter's long-term partnership with Grifols expands our extensive diagnostic product offering and further supports our position as a partner of choice with hospitals and clinical laboratories across the world," stated Arnd Kaldowski, President of Beckman Coulter Diagnostics. Our hemostasis product line complements Beckman Coulter's broad portfolio of products and services for the core laboratory," said Carsten Schroeder, Grifols President of Diagnostic Commercial Operations. "Grifols continues to execute its strategy in growing the Specialty Diagnostics line.
0 kommentar(er)
